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Abstract 36 
Besides their well-described use as delivery systems for water-soluble drugs, 37 
liposomes have the ability to act as a solubilizing agent for drugs with low aqueous 38 
solubility. However, a key limitation in exploiting liposome technology is the 39 
availability of scalable, low-cost production methods for the preparation of 40 
liposomes. Here we describe a new method, using microfluidics, to prepare 41 
liposomal solubilising systems which can incorporate low solubility drugs (in this 42 
case propofol).  The setup, based on a chaotic advection micromixer, showed high 43 
drug loading (41 mol%) of propofol as well as the ability to manufacture vesicles 44 
with at prescribed sizes (between 50 to 450 nm) in a high-throughput setting. Our 45 
results demonstrate the ability of merging liposome manufacturing and drug 46 
encapsulation in a single process step, leading to an overall reduced process time. 47 
These studies emphasise the flexibility and ease of applying lab-on-a-chip 48 
microfluidics for the solubilisation of poorly water-soluble drugs. 49 
  50 
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1 Introduction 51 
The delivery of drugs by liposomes was first described in the 1970s by Gregoriadis 52 
(Gregoriadis and Ryman, 1971) and there is now a range of clinically approved 53 
liposome-based products that improve the therapeutic outcome for patients. 54 
Whilst liposomes are commonly considered for the delivery of aqueous soluble 55 
drugs, they are also well placed to act as solubilisation agents for drugs with low 56 
aqueous solubility. This is of considerable interest given that more than 40% of all 57 
new chemical entities in discovery have low solubility and subsequent issues in 58 
bioavailability (Savjani et al., 2012; Williams et al., 2012). The encapsulation of 59 
low solubility drugs into the bilayer of liposomes allows not only for their 60 
solubilisation in an aqueous media, but furthermore can offer protection from 61 
degradation and control over the pharmacokinetic drug distribution profile and 62 
improved therapeutic efficacy.  63 
 64 
When solubilising drug within the liposomal bilayer, drug incorporation and 65 
release rates has been shown to depend on the properties of the drug, the 66 
composition of the liposomes, the lipid choice and concentration (Ali et al., 2010; 67 
Ali et al., 2013; Mohammed et al., 2004). For example, the log P and molecular 68 
weight are often considered to impact on bilayer loading, and studies have shown 69 
that molecular weight may play a dominant role (Ali et al., 2013). When 70 
considering the design of liposomes, there are a range of parameters that impact 71 
on bilayer loading efficacy.  For example, we have previously shown that 72 
increasing the bilayer lipophillic volume (by adopting longer alkyl chain lipids 73 
within the liposomes) increases the loading ability of liposomal systems 74 
(Mohammed et al., 2004; Ali et al., 2013).  Similarly, incorporation of charged 75 
lipids within the liposomal system may also impact on bilayer loading through 76 
electrostatic repulsion of drugs with like-charged liposomal bilayers (Mohammed 77 
et al., 2004). Incorporation of cholesterol, whilst stabilising the liposomes was also 78 
shown to inhibit bilayer drug loading (Ali et al., 2010) due to the space-filling 79 
action of cholesterol in the liposomal bilayer. By increasing the orientation order 80 
of the phospholipid hydrocarbon chains, cholesterol decreases bilayer 81 
permeability. Indeed, the presence of cholesterol in liposomes solubilising 82 
propofol was shown to shift the drug release profile from zero-order (when no 83 
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cholesterol was present) to first order (when 11 to 33 mol% of cholesterol was 84 
incorporated).  This maps to the idea that without cholesterol the bilayer can be 85 Ǯǯ and less 86 
permeable cholesterol-containing liposome bilayers (Ali et al., 2010).   87 
 88 
However, whilst a wide range of studies have looked at the effect of formulation 89 
parameters on the application of liposomes as solubilising agents, more focus is 90 
required into making liposomes a cost-effective solubilising agent. Recent 91 
advances in lab-on-a-chip based tools for process development has already lead 92 
to microfluidic-based methodologies in drug development (Dittrich and Manz, 93 
2006; Weigl et al., 2003; Whitesides, 2006). Indeed, microfluidics-based methods 94 
(which exploit controlled mixing of streams in micro-sized channels) have been 95 
described for the manufacture of liposomes and lipid nanoparticles (van Swaay, 96 
2013). Liposome formation by microfluidics primarily depends on the process of 97 
controlled alterations in polarities throughout the mixer chamber, which is 98 
followed by a nanoprecipitation reaction and the self-assembly of the lipid 99 
molecules into liposomes. Generally, two or more inlet streams (lipids in solvent 100 
and an aqueous phase) are rapidly mixed together and flow profiles in the 101 
chamber itself are of low Reynolds numbers and categorized as laminar. Using 102 
microfluidic systems a tight control of the mixing rates and ratio between aqueous 103 
and solvent streams is achieved, with lower liquid volumes required, which 104 
facilitates process development by reducing time and development costs. The 105 
systems are designed with the option of high-throughput manufacturing and are 106 
generally considered as less harsh compared to conventional methods of liposome 107 
manufacturing that are based on mechanical disruption of large vesicles into small 108 
and unilamellar ones (Wagner and Vorauer-Uhl, 2011). Within the range of 109 
microfluidic mixing devices, we use a chaotic advection micromixer, a Staggered 110 
Herringbone Micromixer (SHM). The fluid streams are passed through the series 111 
of herringbone structures that allow for the introduction of a chaotic flow profile, 112 
which enhances advection and diffusion. A chaotic advection micromixer, as well 113 
as flow focusing methods, were shown to allow for scalability, associated with 114 
defined vesicle sizes (Belliveau et al., 2012; Jahn et al., 2007). The method based 115 
on chaotic advection was shown to reproducibly generate small unilamellar 116 
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liposomes (SUV) with tight control of the resulting liposome sizes at flow rates as 117 
high as 70 mL/min in a parallelized mixer-setup. We have previously shown that 118 
microfluidics can be used to produce cationic liposomal transfection agents 119 
(Kastner et al., 2014), where design of experiments and multivariate analysis 120 
revealed the ratio between aqueous and solvent phase having a strong relevance 121 
for the formation of size-controlled liposomes. Within this study, we have 122 
exploited microfluidics to develop a high-throughput manufacturing process to 123 
prepare liposomes solubilising drug within their bilayer (Figure 1).  124 
 125 
2 Materials and Methods 126 
2.1 Materials 127 
Egg Phosphatidylcholine (PC) and Cholesterol were obtained from Sigma-Aldrich 128 
Company Ltd., Poole, UK. Ethanol and methanol were obtained from Fisher 129 
Scientific UK, Loughborough, UK. TRIS Ultra Pure was obtained from ICN 130 
Biomedicals, Inc., Aurora, Ohio. Propofol (2,6-Bis(isopropyl)phenol) and 5(6)-131 
Carboxyfluorescein (CF)  was obtained from Sigma-Aldrich Company Ltd., Poole, 132 
UK. 133 
 134 
2.2 Micromixer design and fabrication 135 
The micromixer was obtained from Precision NanoSystems Inc., Vancouver, 136 
Canada. The mixer contained moulded channels which were 200 µm x 79 µm 137 
(width x height) with herringbone features of 50 x 31 µm. 1 mL disposable 138 
syringes were used for the inlet streams, with respective fluid connectors to the 139 
chip inlets.  Formulations using the micromixer were performed on a 140  ? ȋecision NanoSystems Inc., Vancouver, Canada) that allowed 141 
for control of the flow rates (0.5 to 6 mL/min) and the flow ratios (1:1 to 1:5, ratio 142 
between solvent:aqueous) between the respective streams. 143 
2.3 Formulation of small unilamellar vesicles using microfluidics 144 
Lipids (16:4 molar ratio of PC and Cholesterol, 8:1 w/w) were dissolved in ethanol. 145 
SUV were manufactured by injecting the lipids and aqueous buffer (TRIS 10mM, 146 
pH 7.2) into separate chamber inlets of the micromixer. The flow rate ratio (FRR) 147 
(ratio between solvent and aqueous stream) as well as the total flow rate (TFR) of 148 
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both streams were controlled by syringe pumps, calibrated to the syringe inner 149 
diameter. FRR varied from 1:1 to 1:5 and TFR varied from 0.5 to 6 mL/min, 150 
extrapolated from previous reported methods applying a SHM design with a 151 
channel diameter of 200 µm (Kastner et al., 2014). The SUV formulation was 152 
collected from the chamber outlet and dialysed at room temperature against TRIS 153 
buffer (10mM, pH 7.2) for removal of residual solvent. The model drug of low 154 
aqueous solubility was propofol (2,6-Bis(isopropyl)phenol), previously shown to 155 
correspond to high encapsulation values in liposomal systems due to its low 156 
molecular weight (Ali et al., 2013). To encapsulate propofol, the low solubility 157 
drug was dissolved with the lipids in ethanol (0.5 to 3mg/mL) and thereby 158 
liposome formation and encapsulation of the drug was performed simultaneously 159 
using the micromixer method. 160 
 161 
2.4 Lipid film hydration and sonication 162 
Multilamellar vesicles (MLV) were prepared using the lipid film hydration method 163 
(Bangham et al., 1965). Basically, lipids were dissolved in chloroform/methanol 164 
(9:1 v/v) and the organic solvent was subsequently removed by rotary 165 
evaporation under vacuum to form a dry lipid film which was flushed with N2 to 166 
ensure removal of solvent residues. The lipid film was hydrated with TRIS buffer 167 
(10 mM, pH7.2) to form MLV. SUV were then formed via probe sonication 168 
(Sonirep150plus, MSE; 5 min at an amplitude of 5).  169 
 170 
2.5 Measurement of particle characteristics  171 
Characterisation of the liposomes included size measurements using dynamic 172 
light scattering (DLS) (Malvern NanoZS), reported as the z-average (intensity 173 
based mean particle diameter) for monomodal size distributions and the zeta 174 
potential using particle electrophoresis (Malvern NanoZS). Polydispersity (PDI) 175 
measurements (Malvern NanoZS) were used to assess particle distribution. 176 
 177 
2.6 Quantification of drug concentrations 178 
Quantification of propofol was performed by reverse phase HPLC (Luna 5µ C18, 179 
Phenomenex, pore size of 100A, particle size of 5 µm). Detector was UV/Vis, at 268 180 
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nm. The flow rate was constant at 1.0 mL/min throughout with a gradient elution 181 
from 5% B (Methanol), 95% A (0.1% Trifluoroacetic Acid (TFA) in water) to 100% 182 
B over 10 minutes. HPLC-grade liquids were used, sonicated and filtered. The 183 
column temperature was controlled at 35ºC. All analysis was made in Clarity, 184 
DataApex version 4.0.3.876. Quantification was achieved by reference to a 185 
calibration curve produced from standards (six replicates in ethanol) at 186 
concentrations from 0.01 to 1 mg/mL. The calibration curve had a linearity R2  ?187 
0.997, and all measurements were within the level of detection and level of 188 
quantification. 189 
 190 
2.7 Determination of drug loading into liposomes 191 
The amount of drug loaded into the bilayer was measured by determination of the 192 
residual amount of drug in the liposome bilayer after removal of non-entrapped 193 
drug by dialysis (sink conditions) against 1 L of TRIS buffer, 10mM pH 7.2 (3500 194 
Da, Medicell Membranes Ltd., London, UK). The drug content was measured by 195 
HPLC as described in section 2.6. This protocol was validated by assessing the rate 196 
of propofol removal by dialysis.  197 
 198 
2.8 Stability study 199 
For the stability study, formulations of propofol-loaded SUV were stored at 4°C, 200 
25°C and 40°C in pharmaceutical grade stability cabinets over 60 days (time point 201 
measurements at day 0, 7, 14, 21, 28 and 60). Samples were taken at these specific 202 
time points for measurement of particle characteristics (section 2.5) and drug 203 
loading (section 2.6). Samples were dialysed against 500 mL TRIS buffer (10 mM, 204 
pH7.2, sink conditions) at each time point to remove non-entrapped propofol. 205 
Propofol content remaining in the liposome formulation was assessed by HPLC as 206 
described in section 2.6. 207 
 208 
2.9 Recovery of lipids and propofol  209 
To assess the overall lipid and propofol recovery in the microfluidics method, the 210 
amount of lipid and propofol was measured by HPLC and expressed as % recovery 211 
compared to the initial amount of lipids or propofol available in the stock. The 212 
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HPLC method was the same as described section 2.6, and lipids were quantified 213 
by an evaporative light scattering (ELS) detector (Sedere, Sedex 90), set at 52°C 214 
and coupled to the HPLC.  215 
 216 
2.10 Freeze Fracturing Imaging 217 
Two microlitres of liposome suspension were placed in a ridged gold specimen 218 
support and frozen rapidly by plunging into a briskly stirred mixture of 219 
propane:isopentane (4:1) cooled in a liquid nitrogen bath. Fracturing, with a cold 220 
knife, and replication were performed in a Balzers BAF 400D apparatus under 221 
conditions similar to those described previously for freeze-fracture of liposomes 222 
(Forge et al., 1978; Forge et al., 1989). The replicas generated were floated off on 223 
water, cleaned in domestic bleach diluted 1:1 in distilled water, and then washed 224 
several times in distilled water before mounting on grids for electron microscopy. 225 
The replicas were viewed in a JEOL 1200EXII transmission electron microscope 226 
operating at 80kv and digital images collected with a Gatan camera. Images of the 227 
freeze-fractured samples are presented in reverse contrast so that shadows 228 
appear black. Fracturing imaging was performed by Prof. Andrew Forge at UCL 229 
Ear Institute, London, UK.  230 
 231 
2.11 Drug release study 232 
The in-vitro release rate of the drug was determined by incubating the drug-233 
loaded liposomes in 1 L TRIS buffer (10mM, pH 7.2) after removal of the non-234 
incorporated drug, at 37°C in a shaking water bath (150 shakes/min). Three 235 
independent formulations of drug-loaded liposomes made by the microfluidics 236 
method (TFR 2 mL/min, FRR 1:3) and standard lipid film hydration followed by 237 
sonication were incubated (3 mL per formulation) and samples of 200 µL were 238 
withdrawn at time intervals of 0.5 h, 1 h, 2 h, 4 h, 8 h and 16 h. Drug quantification 239 
was performed as described in section 2.6 and expressed as % cumulative release 240 
relative to the initial amount of drug encapsulated. 241 
 242 
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2.12 Incorporation of an aqueous marker within liposomes 243 
To validate the formulation of liposomes, the presence of an aqueous core within 244 
the nanoparticles manufactured was verified by including and imaging of an 245 
aqueous fluorescent dye. Liposomes were manufactured as described in section 246 
2.3 and 2.4 with 1 mM Carboxyfluorescein (CF) included in the aqueous buffer 247 
(TRIS, 10 mM, pH 7.2). Liposomes with entrapped CF were separated from un-248 
entrapped dye by dialysis over night against 1 L fresh TRIS buffer, pH 7.2. 249 
Liposomes were imaged under a confocal microscope SP5 TCS II MP, Leica 250 
Microsystems, Leica TCSSP5 II, 63x objective (HCX PLAPO 63x/1.4-0.6 oil CS). 251 
Images were taken by Charlotte Bland, Aston University, ARCHA facility. 252 
 253 
2.13 Statistical tools 254 
If not stated otherwise, results were reported as mean ± standard deviation (SD). 255 
One- or two-way analysis of variance (ANOVA) was used to assess statistical 256 
significance, followed by Tukeys multiple comparing test and t-test was 257 
performed for paired comparisons. Significance was acknowledged for p values 258 
less than 0.05 (marked with *). All calculations were made in GraphPad Prism 259 
version 6.0 (GraphPad Software Inc., La Jolla, CA). 260 
 261 
3 Results and discussion 262 
3.1 Influence of the flow rate ratio of aqueous and solvent stream on 263 
liposome size 264 
The increase in polarity throughout the chamber drives the formation of small 265 
unilamellar liposomes (SUV) in milliseconds of mixing. For their formation, the 266 
rate of mixing as well as the ratio of aqueous to solvent stream has been 267 
anticipated as crucial factors. The formation of the liposomes is based on a 268 
nanoprecipitation reaction, where supersaturation occurs and the liposomes are 269 
formed by self-assembly after aggregation of the lipid molecules. The initial aim of 270 
this work was to assess the formation of liposomes by microfluidic mixing and 271 
assess the efficacy of this system to act as a solubilising agent. Therefore, 272 
liposomes were prepared from PC and Cholesterol (16:4 molar ratio, 8:1 w/w) at 273 
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different total flow rates (TFR) and flow rate ratios (FRR) and the size, 274 
polydispersity and zeta potential were measured.  275 
 276 
Liposomes formed at low flow rate ratio (1:1) showed the largest size of around 277 
450 nm; increasing the flow rate ratio resulted in smaller liposomes (around 40 - 278 
50 nm) at constant flow rates of 2 mL/min (TRIS, 10 mM, pH7.2) (Figure 2A).  279 
However, increasing the flow rate ratio increased polydispersity (to a maximum 280 
of 0.4; Figure 2B). Liposomes prepared at a flow rate ratio of 1:3 are shown in 281 
Figure 2C, demonstrating their small nature, with average sizes of the vesicles in 282 
agreement with average vesicle diameters obtained by particle sizing via dynamic 283 
light scattering (~40 nm). In contrast, the smallest vesicle size of a comparable 284 
formulation achievable via probe sonication with this lipid formulation was 100 285 
nm in size at PDIs of 0.3 (data not shown). To verify the formation of liposomes, 286 
rather than micelles, the liposomes made by the microfluidics method were 287 
prepared encapsulating an aqueous fluorescent dye, carboxyfluorescein (CF, 1 288 
mM), which was included in the aqueous phase during liposome manufacturing 289 
by microfluidics and lipid film hydration. After removal of the free CF by dialysis 290 
overnight, the remaining dye entrapped in the particles was visualized by confocal 291 
microscopy. Bright green fluorescent cores visible in the particles manufactured 292 
by the microfluidics method (Figure 2D) were in line with images obtained from 293 
liposomes manufactured with the lipid film hydration method (images not 294 
shown); which confirms the presence of aqueous cores and the formation of 295 
liposomes in the novel microfluidics method. 296 
 297 
These impact of flow rate ratio on vesicle size are in agreement with previous 298 
work showing that the increase in FRR reduces the resulting size of the liposomes 299 
(Jahn et al., 2010; Kastner et al., 2014; Zook and Vreeland, 2010). A correlation 300 
between higher flow rate ratios and smaller liposome particles has been reported 301 
using liposomes composed of 1-palmitoyl, 2-oleoyl phosphatidylcholine (POPC), 302 
cholesterol and the triglyceride triolein, which resulted in the production of 303 
vesicular structures with sizes ranging from 140 nm to 40 nm dependent on the 304 	  ? ? ?  ? ? 305 
cores (Zhigaltsev et al., 2012). The overall lower amount of residual solvent 306 
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present at higher FRR employed decreases the particle fusion (Ostwald ripening), 307 
which leads to the formation of smaller particles (Zhigaltsev et al., 2012). The 308 
increase in polydispersity may be a result of increased dilution at higher FRR 309 
reducing the rate of diffusional mixing within the micromixer as noted in previous 310 
studies applying a SHM mixer for liposome manufacturing (Kastner et al., 2014). 311 
With diffusion being proportional to the lipid concentration, increasing FRR is 312 
effectively reducing the lipid concentration, thus reducing the rate of diffusion, 313 
leading to partly incomplete nucleation and a lower rate of liposome formation 314 
inside the micromixer (Balbino et al., 2013b). Overall, these findings demonstrate 315 
that a FRR of 1:2 to 1:4 result in liposomes of the smallest size and polydispersity. 316 
The dilution factor (due to flow ratios chosen involved in the SHM method) is 317 
overall lower compared to ratios employed in the flow-focusing method, which 318 
can reach up to 60 (Jahn et al., 2010; Jahn et al., 2007; Jahn et al., 2004). 319 
Furthermore, the SHM method enhances the diffusional mixing due to the 320 
herringbone structures on the channel wall (Stroock et al., 2002), which results in 321 
an enhanced mixing profiles compared to the flow-focusing technique.  322 
 323 
3.2 Influence of flow rate on throughput and particle characteristics 324 
To assess the ability of the system as a potential high-throughput manufacturing 325 
method for liposomal solubilisation systems, we increased the total flow rate 3-326 
fold whilst maintaining the ratio between aqueous and solvent stream constant. 327 
Liposome size was shown to be independent of the applied flow rate, with no 328 
significant change in vesicle size (Figure 3A), pdi (Figure 3B) and zeta potential (-329 
3±2mV; data not shown). These results support the suitability of microfluidics 330 
manufacturing as a high throughput method with liposome characteristics being 331 
maintained constant whilst increasing the total flow rate in the system. Our results 332 
also confirm that the flow rate ratio used in the system is the most crucial variable 333 
on liposome size, which has previously been demonstrated with other systems 334 
(Balbino et al., 2013a; Balbino et al., 2013b; Jahn et al., 2007; Jahn et al., 2004; 335 
Kastner et al., 2014). The scalability of the microfluidics method has been 336 
suggested by Belliveau et al. 2013, by parallelization of the mixer chamber. 337 
Scalability and increase in throughput together demonstrate the industrial 338 
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applicability comparable with scale-up options available (Wagner and Vorauer-339 
Uhl, 2011). 340 
 341 
As shown, the increase in FRR is the main contributing factor governing liposome 342 
size (Figure 2A). Nevertheless, an increase in FRR will inevitably lead to dilution 343 
and lower liposome concentrations in the final liposome suspension produced. A 344 
subsequent concentration process based on filtration (Pattnaik and Ray, 2009), 345 
chromatography (Ruysschaert et al., 2005) or centrifugation adds additional 346 
processing time. Therefore, to circumvent this additional process step, we 347 
counteracted the dilution of the lipids at higher FRR by increasing initial lipid 348 
concentrations introduced to the micromixer at the desired FRR. Through this 349 
method, liposomes were manufactured at up to 6 fold higher concentrations. 350 
Increased lipid concentrations at FRR of 1:3 and 1:5 did not significantly (p>0.05) 351 
influence size and polydispersity compared to the standard lipid concentration 352 
(Figure 4A and B), whereas at a FRR of 1:1 a significant (p<0.05) decrease in 353 
vesicle size was observed (Figure 4A). At this lower FRR, the higher lipid 354 
concentrations may again decreasing particle fusion leading to the formation of 355 
smaller particles (Zhigaltsev et al., 2012). Nevertheless, this setup allows to 356 
increase the final liposome concentration according to the FRR chosen without 357 
adversely changing resulting vesicle size or polydispersity for the smallest vesicle 358 
sizes obtained at higher FRR (Figure 4A and B respectively), due to the diffusional 359 
mixing process in the SHM design. 360 
 361 
3.3 Drug loading studies: The effect of drug encapsulation by the liposome 362 
manufacturing method  363 
So far, we have shown that the microfluidics method allows for size-controlled and 364 
rapid synthesis of liposomes. To consider the applicability of this method to be 365 
used for a high-throughput production of liposomes as solubilising agents the 366 
loading capacity of the formulation was considered. Based on the optimisation 367 
studies shown in Figure 2, propofol was solubilised within liposomes prepared at 368 
a FRR of 1:3 and a TFR of 2 mL/min. The particle characteristics and drug loading 369 
efficiency (mol%; Figure 5A) was determined at propofol concentrations ranging 370 
from 0.5 to 3 mg/mL (effective concentration in the solvent stream).  371 
14 
 
 372 
Using a propofol concentration of 1 mg/mL in the solvent stream showed high 373 
drug loading (~50 mol%), combined with particle size of ~50 nm and a low 374 
polydispersity (Figure 5A).  Particle size and polydispersity increased notably (ca. 375 
600 nm and 0.8 respectively) at the highest propofol concentration (3 mg/mL in 376 
the solvent stream, giving a loading of ~25mol%, Figure 5A), suggesting the 377 
liposome system may have become saturated or destabilised at high propofol 378 
concentrations (drug-to-lipid ratio 1.72 mol/mol).  Based on this, subsequent 379 
studies adopted a propofol concentration at 1 mg/mL in the solvent stream for all 380 
performed encapsulation studies.  381 
 382 
The drug encapsulation was further investigated as a function of FRR in the 383 
microfluidics method. Propofol encapsulation (mol%) in liposomes prepared at 384 
FRR 1:1, 1:3 and 1:5 remained at approximately 50 mol% with no statistical 385 
difference. However this was significantly higher (p< 0.0001) than drug loading in 386 
liposomes prepared via sonication (15 mol%; Figure 5B). The drug loading 387 
efficiency of liposomes prepared by sonication is in line with previous reported 388 
propofol encapsulation (Ali et al., 2013). Furthermore, drug encapsulation did not 389 
alter vesicle size or polydispersity (Figure 5A) and vesicle sizes obtained by 390 
dynamic light scattering were verified by freeze fracturing images (Figure 5D). 391 
This higher drug loading may be a result of the highly efficient mixing processes 392 
occurring during microfluidics that favours incorporation of propofol within the 393 
bilayers in the same process as the vesicles form. Indeed, the here presented 394 
method allows to achieve a propofol encapsulation of ~50 mol%, which 395 
represents a total propofol amount of ~300 mg/mL in the final liposome 396 
formulation, representing a 2000-fold increase to the reported aqueous solubility 397 
of propofol, 150 µg/mL (Altomare et al., 2003).  398 
 399 
To consider, drug release profiles, the in-vitro release of propofol encapsulated in 400 
liposomes by microfluidics was monitored at 37°C over 16 h. Liposomes formed 401 
with the microfluidics method had a significant higher drug encapsulated at the 402 
start of the release study (~55 mol%) compared to those vesicles formed by 403 
sonication (20 mol% drug encapsulation). However, relative to initial loading, an 404 
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initial release of ca 40% was observed at 1 h for both formulations, followed by a 405 
continuous release of 90% of the encapsulated drug was observed over 8 h (Figure 406 
6). Whereas the fatty alcohol alkyl chain length was shown to affect the release 407 
profile of encapsulated propofol (Ali et al., 2013),  here the method of liposome 408 
manufacturing was shown to mainly affect the amount of drug incorporated into 409 
the liposomes, without altering the release profile of the encapsulated drug 410 
against sink conditions. Previous we have shown that solubilisation of propofol in 411 
phosphatidylcholine liposomes followed a zero-order release kinetics, where the 412 
incorporation of a higher amount of cholesterol shifted the release rates towards 413 
a first-order release model (Ali et al., 2010), implying that the release kinetics 414 
itself are mainly dominated by the lipid composition and physicochemical 415 
characteristics rather than the method of liposome manufacturing. This may 416 
prove advantageous in the development of an IV formulation; the 417 
pharmacokinetic release profile of propofol has been studies previously in a 418 
colloidal dispersion between 20-100 nm (Cai et al., 2012), where rapid 419 
distribution of propofol compared to the commercial product Diprivan® 420 
highlighted the need on the development of new techniques for the encapsulation 421 
of low solubility drugs.  422 
 423 
It is important to verify both lipid and drug recovery when using the microfluidics 424 
method, to ensure cost-effectiveness and that lipid and drug concentrations 425 
remain locked at the ratio initially designed prior to formulation. To date, the 426 
quantification of lipids is mainly dominated by time intensive assays like mass 427 
spectrometry (Moore et al., 2007). Here, we introduce a simple and robust method 428 
of lipid quantification based on evaporative light scattering (ELS) detection and 429 
HPLC separation. We coupled an ELS detector downstream a HPLC separation 430 
method, which allowed for quantification of any solids in the eluate with a lower 431 
volatility than the mobile phase. Microfluidics based liposomal-drug formulations 432 
showed good recovery of the drug (88 - 92%; Figure 5C), independent of the FRR. 433 
Similarly, lipid recovery was high at FRR of 1:1 and 1:3 (97% and 89%; for FRR 434 
1:1 and 1:3 respectively; Figure 5C). A significant drop (79%; p<0.01) in lipid 435 
recovery was noted at a flow ratio of 1:5, suggesting that higher FRR employed in 436 
the microfluidics method may impede lipid recovery due to enhanced dilution in 437 
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the chamber. Nevertheless, the smallest vesicle size (~50nm) can be obtained at a 438 
FRR of 1:3 (Figure 2A) and any further increase in FRR will not benefit the 439 
formulation (size, pdi and drug encapsulation). Based on this, we chose the FRR 440 
1:3 for a long-term stability study. 441 
 442 
3.4 The effect of manufacturing methods on liposome stability and drug 443 
encapsulation over 8 weeks  444 
The SHM method was previously investigated for the encapsulation of a highly 445 
soluble drug, with approximately 100% loading efficiencies being reported using 446 
doxorubicin as a model drug (Zhigaltsev et al., 2012); the authors demonstrated 447 
high drug retention of encapsulated drug with liposomes stored at 4°C over the 448 
course of eight weeks (Zhigaltsev et al., 2012).  Following the assessment that 449 
liposomes manufactured by the microfluidics method yields significant higher 450 
encapsulation of propofol, similarly we performed an eight-week stability study 451 
to verify the integrity of the vesicles at different storage temperatures. Vesicles 452 
were prepared using microfluidics as described above, and the initial amount of 453 
propofol encapsulated was determined after removal of free drug by dialysis. 454 
Vesicles were stored at 4°C, 25°C/60%RH and 40°C/75%RH (standard ICH 455 
temperatures) in pharmaceutical grade stability cabinets and the formulations 456 
made by the sonication method were stored at 25°C/60%RH (Figure 7, Table 1), 457 
acting as the control method. The control liposomes formed by sonication showed 458 
good stability in terms of size retention over the course of the study. Similarly, for 459 
liposomes prepared using microfluidics, vesicle size remained  unaffected after 460 
storage over 8 weeks at 4°C and 25°C. In contrast, liposomes stored at 40°C 461 
significantly increase in size from initially 55 nm to 120 nm (Figure 7A), with no 462 
notable affect to polydispersity, suggesting the liposome population as a whole 463 
has changed in size rather than a sub-set of the vesicles (Table 1).   464 
 465 
Minor (but not significant) drug loss from the liposomes was detected for the 466 
formulations at 4°C and 25°C after the first 7 days of storage (Figure 7B), after 467 
which the formulations remained stable with final drug encapsulation values of 468 
41±1 mol% and 41±4 mol% at 4°C and 25°C storage conditions respectively 469 
(Figure 7B).  Similarly, with liposomes formulated using sonication showed and 470 
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initial drug loss when stored at 25°C/60%RH which then plateaued out (Figure 471 
7B).  Notable drug loss from the microfluidic systems was only seen when they 472 
were stored at elevated temperatures with the formulation stored at 40°C 473 
showing almost complete drug loss over the course of the stability study, with only 474 
5±1 mol% drug remaining encapsulated after 8 weeks, similar to the final drug 475 
encapsulated in the sonicated liposomes which were stored at 25°C/60%RH 476 
(Figure 7B). Overall, vesicles produced with the microfluidics method were 477 
smaller with a lower polydispersity than those obtained by lipid film hydration / 478 
sonication. The vesicles manufactured by sonication maintained their size around 479 
100±20 nm throughout the stability study (stored at 25°C) as well as their 480 
polydispersity (Table 1). Results suggest that the method of manufacturing mainly 481 
impacts the drug encapsulation rather than the physical properties (size, pdi, zeta 482 
potential). Stability of the formulations is crucial and these results demonstrate 483 
that liposomes formed by the microfluidics method remain over two months at 484 
conditions of 4 and 25°C. 485 
 486 
3.5 Conclusion 487 
Here, for the first time, we have demonstrated a high-throughput, robust method 488 
of preparing size-controlled liposomes as solubilising agents using microfluidics. 489 
These liposomes have well defined, scalable, process controlled, physico-chemical 490 
attributes demonstrating this method is suitable for pre-clinical and clinical 491 
production of liposomes. Drug loading was shown to be in an applicable range for 492 
clinical application (Biebuyck et al., 1994). Furthermore, using this novel method, 493 
liposome manufacturing and drug encapsulation are processed in a single process 494 
step, circumventing an additional drug loading step downstream, which notably 495 
reduces the time for production of stable drug-loaded vesicles of specified 496 
physico-chemical characteristics.  497 
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Tables 595 
Table 1: Polydispersity at different storage conditions for 8 weeks. Results are 596 
mean out of triplicate formulations and measurements. 597 
Day 0 7 14 21 28 60 
Microfluidics       
4°C  0.403 ± 0.02 0.286 ± 0.01 0.282 ± 0.01  0.295 ± 0.01 0.261 ± 
0.01 
0. 305 ± 0.01 
25°C  0.403 ± 0.02 0.295 ± 0.01 0.279 ± 0.01 0.301 ± 0.04 0.302 ± 
0.03 
0.266 ± 0.03 
40°C 0.403 ± 0.02 0.254 ± 0.001 0.121 ± 0.02 0.119 ± 0.001 0.129 ± 
0.01 
0.221 ± 0.01 
Sonication       
25°C  0.656 ± 0.02 0.652 ± 0.02 0.522 ± 0.15 0.658 ± 0.049 0.552 ± 
0.04 
0.505 ± 0.06 
  598 
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Figures 599 
 600 
 601 
Figure 1: Schematic depiction of the liposome formation process based on the 602 
SHM design, a chaotic advection micromixer for (A) empty liposomes, (B) drug 603 
loaded liposomes and (C) chamber layout. 604 
 605 
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 606 
Figure 2: Liposome size (A) and polydispersity (B) of vesicles formulated with 607 
microfluidics method at increasing flow ratios. ns = not significant (p>0.05), * 608 
denotes statistical significance (p<0.05) in comparison to FRR 1:1  (C) Freeze 609 
fracturing electron microscopy images for empty liposomes manufactured with 610 
the microfluidics method. Bar represents 100 nm. (D) Fluorescent microscope 611 
images of liposomes manufactured with the microfluidics method, 612 
carboxyfluorescein was encapsulated within the aqueous core of the vesicles as a 613 
control for the manufacturing of bilayer liposomes. Bar represents 20 µm.   614 
 615 
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616 
Figure 3: Liposome size (A) and polydispersity (B) of vesicles formulated with 617 
microfluidics at increasing flow rates and constant flow ratio of 1:3, n = 3, ns = not 618 
significant (p>0.05). 619 
 620 
 621 
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622 
Figure 4:  Increase in the lipid concentration in the ethanol stock to circumvent 623 
the dilution effect at flow ratios of 1:1, 1:3 and 1:5 for (A) liposome size, * denotes 624 
statistical significance (p<0.05) in comparison to FRR 1:1 for the standard lipid 625 
concentration and (B) polydispersity with respective concentration of PC and 626 
Cholesterol in the inlet stream, n = 3. 627 
 628 
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629 
Figure 5: (A) Effect of drug concentrations in the ethanol inlet stream (0.5, 1 and 630 
3 mg/mL) on encapsulation efficiency (mol%), particle size and polydispersities 631 
at a flow ratio of 1:3.. (B) Encapsulation efficiency (mol%) of liposomes formed 632 
with the microfluidics method at flow ratios of 1:1, 1:3 and 1:5 compared to the 633 
encapsulation efficiency using the sonication method. Results are average out of 634 
triplicate formulations and measurements. ns = not significant (p>0.05), * denotes 635 
statistical significance (p<0.00001) in comparison to microfluidics-based 636 
samples. (C) Recovery of lipids and propofol in the microfluidics method at 637 
different flow ratios. Results are expressed as % compared to the initial lipid and 638 
propofol amount present (n = 3). (D) Freeze fracturing electron microscopy 639 
images for liposomes loaded with the low solubility model drug (propofol) 640 
manufactured with the microfluidics method. Bar represents 100 nm 641 
 642 
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643 
Figure 6: Effect of manufacturing method to the drug release of propofol from 644 
liposomes. Results show the cumulative drug release profile from formulations 645 
manufactured with the standard lipid film hydration / sonication method and 646 
microfluidics and represent percentage cumulative release of initially entrapped 647 
propofol, expressed as the means of three experiments ± SD. 648 
 649 
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650 
Figure 7: Size (A) and drug encapsulation (mol%) (B) at different storage 651 
conditions over 8 weeks. Results are mean of triplicate formulations and 652 
measurements. 653 
